	US 11,666,649 B2
	Vectors and vaccine cells for immunity against Zika virus
Natasa Strbo, Miami, FL (US); and Laura Romero, Miami, FL (US)
Assigned to University of Miami, Miami, FL (US)
Appl. No. 16/334,637
Filed by University of Miami, Miami, FL (US)
PCT Filed Oct. 10, 2017, PCT No. PCT/US2017/055912 § 371(c)(1), (2) Date Mar. 19, 2019, PCT Pub. No. WO2018/071405, PCT Pub. Date Apr. 19, 2018.
Claims priority of provisional application 62/406,506, filed on Oct. 11, 2016.
Prior Publication US 2021/0290750 A1, Sep. 23, 2021
Int. Cl. A61K 39/12 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55 (2013.01); C07K 2319/30 (2013.01); C07K 2319/35 (2013.01); C12N 2770/24134 (2013.01)]

12 Claims

1. An expression vector system comprising:

(i) a nucleic acid encoding a fusion protein comprising a chaperone protein and an Fc fragment of an IgG immunoglobulin, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 8, and

(ii) a nucleic acid encoding a flavivirus protein, or an antigenic portion thereof, wherein the flavivirus protein is a Zika virus protein,

wherein each nucleic acid is operably linked to a promoter.